Drug Database
AC

aciclovir + hydrocortisone (Xerese / Xerclear / Lipsovir)

✓ Approved

Lapidot Medical · NR3C1 · Small Molecule

What is aciclovir + hydrocortisone?

aciclovir + hydrocortisone is a small molecule developed by Lapidot Medical. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesXerese, Xerclear, Lipsovir
CompanyLapidot Medical
Drug ClassSmall Molecule
Molecular TargetNR3C1, ,
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, Lapidot Medical

Mechanism of Action

Molecular Targets

aciclovir + hydrocortisone acts on 3 molecular targets:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
(UL30)
(UL30)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

aciclovir + hydrocortisone is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersCongenital herpes simplex infection✓ Approved

Related Research Articles

PubMedIranian journal of pharmaceutical research : IJPR2026-09-20

Protective Effect of Soy Lecithin Liposomes in Oxazolone-Induced Dermatitis in a Mouse Model: A Comparative Evaluation.

Partoazar Alireza A, Alemi Maryam M, Mirzaee Saffari Partow P, Eskandary Nasab Maryam M et al.

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense itching, severe erosion, and rashes on the skin surface. Prolonged AD may cause hemorrhage and secondary infections due to scratching. This study aimed to investigate the anti-AD effects of soy lecithin (SL) applied topically to oxazolone (OX)-treated skin in a mouse model. The effects of SL and hydrocortisone (HC), used as the standard drug, on behavioral responses such as scratching and grooming were evaluated during a 35-day trial. Histopathology and immunohistochemistry (IHC) for the cytokines TNFα and IL8 were also evaluated in the skin of the treated mice. Topical administration of SL showed efficacy comparable to that of HC and significantly alleviated itching and grooming behaviors in eczematous animals. Topical SL also improved symptoms, including skin erythema, scarring, and edema, as well as histopathological parameters in AD mice. IHC analysis indicated that SL administration effectively reduced tissue levels of the inflammatory cytokines TNFα and IL8 in AD mice. Topical SL significantly improved AD severity in an OX-induced mouse model of AD. These results support further preclinical studies before clinical investigations in humans are undertaken.

PMID 42763650
Read full article →
PubMedEndocrine regulations2026-09-19

Prescription pattern of oral hydrocortisone by Indian healthcare professionals: An online questionnaire-based survey.

Valia Rama R, Jangir Ashish Kumar AK, Sahu Danendra D, Menon Jayakrishnan C JC et al.

Objective. Adrenal insufficiency is predominantly managed by glucocorticoids, from which hydrocortisone is most frequently prescribed. However, limited data are available on prescription patterns among Indian healthcare professionals (HCPs). This study assessed the prescription practices of hydrocortisone among Indian HCPs and evaluated their awareness of tapering protocols and necessity for modified-release formulations of hydrocortisone. Methods. This online questionnaire-based survey involved 300 HCPs across India who prescribe oral hydrocortisone for various endocrinological and non-endocrinological indications. Google Forms were used and survey was carried out over a period of two months. Only fully accomplished responses were included in the analysis and the response rate was calculated. Results. The survey response rate was 84.27%. Among HCPs, 94.7% prescribed oral hydrocortisone with 47.5% using it often and 28.9% very often. Prescription frequency varied from 29.9% (prescribed once weekly) to 25.7% (two or more times weekly). Awareness of approved indications was high (96.8%). Tapering protocols were widely practiced (95.4%) often or very often by 82.7% HCPs. Hydrocortisone was mainly prescribed for primary adrenal insufficiency (77.5%), secondary adrenal insufficiency (63.0%), and congenital adrenal hyperplasia (55.6%). Frequent adverse events included hyperglycemia (43.3%) and weight gain (43.0%). Most HCPs (89.8%) felt need for sustained-release hydrocortisone, particularly for primary adrenal insufficiency (81.7%). Alternatives of hydrocortisone mainly included prednisolone (65.8%), prednisone (37.3%), and dexamethasone (21.8%). Conclusion. Indian HCPs frequently prescribe oral hydrocortisone and are well-versed in tapering protocols. However, frequent adverse events and unmet needs emphasize strong demand for modified-release formulations, particularly for management of adrenal insufficiency.

PMID 42762503
Read full article →
PubMedFrontiers in pharmacology2026-09-19

Drug spectrum and disproportionality signals for diabetes insipidus in FAERS: multi-method analysis, JADER cross-database assessment, and PubMed-based case-level evidence.

Li Yiqi Y, Zhou Yu Y, Tian Jinghe J, Wei Deyi D et al.

The aim of this study is to characterize reporting patterns and non-treatment drug safety signals for diabetes insipidus (DI) in the FDA Adverse Event Reporting System (FAERS), evaluate signal stability using crude, adjusted, and shrinkage-based disproportionality methods, and assess signal reproducibility in the Japanese Adverse Drug Event Report (JADER). We analyzed FAERS (2004Q1-2025Q4) and JADER (2004-2025) reports. DI cases were defined by MedDRA Preferred Terms "Diabetes insipidus" and "Nephrogenic diabetes insipidus"; central DI-related lower-level terms mapped to "Diabetes insipidus" and were not separately retrievable. Drugs used for DI diagnosis/treatment or arginine vasopressin (AVP)-deficiency states were excluded during preprocessing. All eligible non-treatment primary suspect drug-DI pairs were screened, and the main multi-method summary focused on the 50 most frequently reported drugs. Published cases were summarized as case-level evidence, not comparative risk meta-analysis. FAERS contained 3,444 Preferred Term (PT)-defined DI reports; 3,325 entered the main non-treatment analysis. Raw annual counts increased, whereas normalized reporting proportions fluctuated. Complete screening identified 112 crude reporting odds ratio (ROR)-positive drug-DI pairs. Among the frequency-ranked top 50, 47 met crude ROR criteria, 38 remained positive after adjustment, 32 met empirical Bayes geometric mean (EBGM) criteria, and 40 met information component (IC) criteria; in addition, 36 were positive in at least three methods. In JADER, 696 DI reports entered cross-database assessment; eight drugs met crude ROR criteria, eight met adjusted ROR criteria, three met EBGM criteria, and three met IC criteria. Lithium, hydrocortisone, and propofol were positive across all four JADER methods. After treatment-drug exclusion, DI reports clustered mainly among nervous system, antineoplastic/immunomodulating, and systemic hormonal agents. Several non-treatment drugs showed persistent disproportionality, but JADER support was limited. These findings are hypothesis-generating signals, not causal evidence.

PMID 42761208
Read full article →
PubMedCureus2026-09-18

De Morsier Syndrome Associated With Megalocornea: Impact of Hormone Replacement Therapy on the Resolution of Neonatal Cholestasis.

Nicolas Mbaihorem M, Houda Khellouk K, Atrassi Meriem M, Bensabbahia Dalal D

De Morsier syndrome, or septo-optic dysplasia (SOD), is a rare congenital malformation characterized by optic nerve hypoplasia, midline brain abnormalities, and pituitary hormone deficiencies. Neonatal presentation can be misleading, particularly when it manifests as cholestatic jaundice. We report the clinical, biochemical, and radiological evaluation of a two-month-old male infant admitted for persistent neonatal cholestatic jaundice, progressive weight faltering, and recurrent hypoglycemia. Slit-lamp examination, comprehensive endocrine workup, and brain magnetic resonance imaging (MRI) were performed to establish the diagnosis. Written informed consent was obtained from the patient's parents (or legal guardians) for publication of this case report and any accompanying images. Physical examination revealed horizontal nystagmus and bilateral megalocornea (diameter > 13 mm). Laboratory investigations showed cholestasis with normal gamma-glutamyl transferase (GGT) levels and recurrent hypoglycemia, which led to the diagnosis of combined anterior pituitary hormone deficiency (growth hormone, thyroid-stimulating hormone, and adrenocorticotropic hormone). Brain MRI confirmed the diagnosis by showing agenesis of the septum pellucidum, bilateral optic nerve hypoplasia, and an ectopic posterior pituitary gland. Targeted hormone replacement therapy with L-thyroxine (10 μg/kg/day) and hydrocortisone (5 mg/kg/day) led to a complete resolution of the cholestasis within three weeks, alongside blood glucose stabilization and weight gain. Neonatal cholestasis is a classic early manifestation of SOD due to impaired bile acid transporter maturation caused by endocrine deficits. Its association with megalocornea highlights the variability of embryonic anterior segment anomalies. Early diagnosis is vital to initiate prompt hormone therapy, ensure hepatic recovery, and optimize neurodevelopmental outcomes.

PMID 42756607
Read full article →
PubMedJCEM case reports2026-09-17

Glucocorticoid-induced adrenal insufficiency from a supplement containing undisclosed dexamethasone.

Fatima Hameeda H, Johal Lovepreet L, Ibrahim Ahmed A, Ghotra Gurinder G et al.

Glucocorticoid-induced adrenal insufficiency (GIAI) is a very common cause of adrenal insufficiency, resulting from exogenous glucocorticoid exposure leading to suppression of the hypothalamic-pituitary-adrenal axis. While typically due to prescribed glucocorticoids, hidden ingredients in supplements may also contribute to this exposure. We describe a case of a 52-year-old male who presented with recurrent gastrointestinal symptoms of nausea and vomiting. Clinical features included persistent sinus tachycardia, hyponatremia, hypokalemia, and hypomagnesemia. The initial work-up was unrevealing; additional testing revealed a low random cortisol level, an inadequate response to cosyntropin stimulation, and an inappropriately normal adrenocorticotropic hormone level, confirming secondary adrenal insufficiency. Treatment with hydrocortisone resulted in improvement of the patient's clinical symptoms. Further history uncovered that the patient had abruptly discontinued a daily supplement named "Force Forever," which, according to the US Food and Drug Administration (FDA), contains undisclosed ingredients, including diclofenac and dexamethasone. Although the FDA has issued a warning regarding this supplement, there have been no reported cases of GIAI from its use in the United States. This case emphasizes the importance of comprehensive history taking and considering adrenal insufficiency in the differential diagnosis for patients presenting with refractory, unexplained gastrointestinal symptoms like nausea and vomiting.

PMID 42751107
Read full article →
PubMedHCA healthcare journal of medicine2026-09-17

Myxedema Coma with Cardiogenic Shock: Diagnostic Challenges and Risks of Amiodarone in Acute Thyroid Failure.

Cardona Jean Carlos Ramos JCR, Mundhra Gunjan G, Egbo Munachiso M, Melnychuk Veniamin V et al.

Myxedema coma is a rare but life-threatening manifestation of severe hypothyroidism characterized by altered mental status, hypothermia, bradycardia, and multiorgan dysfunction. Delayed diagnosis is common, particularly in elderly patients with multiple comorbidities. Cardiac complications, including malignant arrhythmias, are underrecognized contributors to morbidity and mortality. Profound hypothyroidism compromises cardiac myocyte function through reduced activity of enzymes involved in calcium uptake, leading to impaired myocardial contraction and relaxation. This results in decreased heart rate, reduced cardiac output, and altered left ventricular function, which may be further exacerbated in patients with heart failure with reduced ejection fraction. Prolongation of the ventricular action potential and QT interval is frequently observed, predisposing the patient to ventricular irritability and malignant arrhythmias, including acquired torsades de pointes. A 72-year-old woman with hypothyroidism, heart failure with reduced ejection fraction, chronic kidney disease, and a history of breast cancer presented to the emergency department with progressive weakness, dyspnea, edema, and confusion. Laboratory evaluation revealed the thyroid-stimulating hormone to be greater than 150 mIU/L and free thyroxine to be less than 0.3 ng/dL, which is consistent with severe hypothyroidism. A Popoveniuc diagnostic score of 95 was calculated, supporting a diagnosis of myxedema coma. The patient developed transient wide-complex tachycardia and was treated with intravenous (IV) amiodarone. She subsequently experienced worsening encephalopathy, hypotension, and bradyarrhythmia, which required intubation, multiple vasopressors, IV levothyroxine, hydrocortisone, fludrocortisone, and mechanical ventilation. Transthoracic echocardiography demonstrated a left ventricular ejection fraction of 12%. Her course progressed to cardiogenic shock necessitating biventricular mechanical circulatory support and continuous renal replacement therapy prior to transferring to a tertiary care center. This case illustrates the complex interplay between severe hypothyroidism, advanced systolic heart failure, QT prolongation, and ventricular tachyarrhythmias in myxedema coma. Although amiodarone is commonly used for ventricular arrhythmia management due to its acute electrical stabilizing properties, its effects on thyroid hormone metabolism warrant caution in patients with underlying thyroid disease. Early recognition and coordinated endocrine cardiac management are critical to improving outcomes in this high-risk population.

PMID 42751383
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about aciclovir + hydrocortisone